Norris Perne & French LLP MI Sells 1,152 Shares of Charles River Laboratories Intl. Inc (CRL)

Norris Perne & French LLP MI trimmed its holdings in Charles River Laboratories Intl. Inc (NYSE:CRL) by 1.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,952 shares of the medical research company’s stock after selling 1,152 shares during the quarter. Charles River Laboratories Intl. makes up about 1.7% of Norris Perne & French LLP MI’s holdings, making the stock its 18th biggest position. Norris Perne & French LLP MI owned 0.20% of Charles River Laboratories Intl. worth $12,909,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. NumerixS Investment Technologies Inc acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at $122,000. Wsfs Capital Management LLC acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at $203,000. CIBC Private Wealth Group LLC acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at $212,000. Dynamic Technology Lab Private Ltd acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at $212,000. Finally, Visionary Asset Management Inc. acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at $214,000. 96.02% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have issued reports on CRL shares. Robert W. Baird boosted their price objective on shares of Charles River Laboratories Intl. from $133.00 to $141.00 and gave the company an “outperform” rating in a research note on Monday, September 17th. Credit Suisse Group dropped their price objective on shares of Charles River Laboratories Intl. from $129.00 to $121.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 21st. Raymond James raised shares of Charles River Laboratories Intl. from a “market perform” rating to an “outperform” rating and set a $140.00 price objective on the stock in a research note on Thursday, August 23rd. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 28th. Finally, Argus boosted their price objective on shares of Charles River Laboratories Intl. from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, August 27th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Charles River Laboratories Intl. has an average rating of “Buy” and an average price target of $128.50.



In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $120.05, for a total transaction of $149,942.45. Following the sale, the insider now directly owns 13,690 shares in the company, valued at approximately $1,643,484.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Deborah Turner Kochevar sold 4,066 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $123.66, for a total transaction of $502,801.56. Following the sale, the director now owns 10,190 shares in the company, valued at $1,260,095.40. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by insiders.

Shares of NYSE CRL traded down $0.67 during trading on Monday, hitting $117.60. 15,823 shares of the company were exchanged, compared to its average volume of 416,323. The firm has a market capitalization of $5.68 billion, a P/E ratio of 22.32, a PEG ratio of 1.48 and a beta of 0.65. Charles River Laboratories Intl. Inc has a 1 year low of $96.70 and a 1 year high of $135.90. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.48 and a current ratio of 1.72.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, August 8th. The medical research company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.46 by $0.16. The company had revenue of $585.30 million for the quarter, compared to analyst estimates of $570.65 million. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The business’s revenue was up 24.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.29 EPS. On average, sell-side analysts forecast that Charles River Laboratories Intl. Inc will post 5.91 earnings per share for the current fiscal year.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Stock Symbols and CUSIP Explained

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply